PR96279

PEYNIER, France, June 1, 2022 /PRNewswire=KYODO JBN/ --

PMB announces the launch of the FLASHKNiFE Consortium, supported by the

European Institute of Innovation & Technology for Health (EIT Health). This

European public-private partnership aims at advancing radiation therapy by

introducing a new radiotherapy device into clinical practice.

More than 10 million patients receive radiation therapy each year worldwide,

making it an essential tool for cancer treatment, along with surgery and

chemotherapy. Moreover, 30% to 40% of treated patients are resistant to

radiotherapy. Radiation-induced side effects severely limit the radiation dose

given to the tumor. If toxicity could be reduced, a greater dose of radiation

could be given, providing a more efficient and better tolerated outcome in

cancer treatment.

The FLASHKNiFE Consortium aims to address this challenge by using FLASH

radiation therapy, a recently discovered method of administering radiotherapy.

Given in a single, very short treatment session, FLASH radiotherapy has been

shown to cause less side effects than conventional radiotherapy in several

preclinical and clinical studies.

The Consortium brings together high-profile institutions across Europe who will

be working over the next three years to achieve this goal: PMB, Alcen, Institut

Gustave Roussy, Centro Hospitalar Lisboa Norte, Universitatsklinikum Erlangen

and ProductLife Group. With a total budget of Euro 8.2 million, FLASHKNiFE is

co-funded by the EIT Health (Euro 2.5M) and the partners.

To advance the clinical application of FLASH radiotherapy, the FLASHKNiFE

Consortium as well as our additional clinical partner CHUV, will conduct a

multi-centric clinical investigation on skin cancer, starting in 2023.

Prof. Eric Deutsch, Head of Gustave Roussy Radiotherapy Department, says: "the

decision to embark on this very exciting EIT Health project was made because it

brought together a biological innovation, the FLASH concept, a technology

innovation, FLASHKNiFE, and the ability to turn these innovations into reality

for the patient."

About PMB:

PMB is an innovative company specialized in the design and manufacture of

complex mechanical assemblies for the industries of Defense, Medical and

Research. Since the late 2000s, the company has developed complex systems

integrating particle accelerators for nuclear medicine, non-destructive

testing, and a FLASH radiotherapy system. PMB is a subsidiary of Alcen, an

industrial diversified French group with a strong focus on innovation advancing

societal challenges.

For more information visit: www.pmb-alcen.com　    

Press Information:

Fatine Slaoui

flashknife-consortium@pmb-alcen.com

+33 4 42 53 13 13

Home page | FLASHKNiFE project [ https://flashknife-project.com/ ]

Video - https://mma.prnewswire.com/media/1829780/FLASHKNiFE_Consortium.mp4

Photo - https://mma.prnewswire.com/media/1829764/FLASHKNiFE_Consortium_1.jpg

Photo - https://mma.prnewswire.com/media/1829762/FLASHKNiFE_Consortium_2.jpg

Logo - https://mma.prnewswire.com/media/1829763/FLASHKNiFE_Consortium_Logo.jpg

Source: PMB-Alcen and FLASHKNiFE Consortium